See more : Buzzi Unicem S.p.A. (BZZUF) Income Statement Analysis – Financial Results
Complete financial analysis of Wuhan General Group (China), Inc. (WUHN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Wuhan General Group (China), Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Dassault Systèmes SE (DSY.PA) Income Statement Analysis – Financial Results
- Melstar Information Technologies Limited (MELSTAR.BO) Income Statement Analysis – Financial Results
- Azimut Exploration Inc. (AZMTF) Income Statement Analysis – Financial Results
- The SPAR Group Ltd (SGPPY) Income Statement Analysis – Financial Results
- Baudax Bio, Inc. (BXRX) Income Statement Analysis – Financial Results
Wuhan General Group (China), Inc. (WUHN)
About Wuhan General Group (China), Inc.
Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Pointe-Claire, Canada.
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 14.18K | 33.28K | 0.00 |
| Cost of Revenue | 12.80K | 15.80K | 0.00 |
| Gross Profit | 1.38K | 17.47K | 0.00 |
| Gross Profit Ratio | 9.70% | 52.51% | 0.00% |
| Research & Development | 22.28K | 8.39K | 35.89K |
| General & Administrative | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 1.66M | 129.58K | 143.73K |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.69M | 137.96K | 179.62K |
| Cost & Expenses | 1.70M | 153.77K | 179.62K |
| Interest Income | 201.00 | 3.00 | 0.00 |
| Interest Expense | 6.64K | 5.36K | 30.77K |
| Depreciation & Amortization | 4.15K | 206.30K | 171.86K |
| EBITDA | -1.70M | 415.36K | -179.62K |
| EBITDA Ratio | -12,010.84% | -362.09% | 0.00% |
| Operating Income | -1.68M | -120.49K | -179.62K |
| Operating Income Ratio | -11,882.90% | -362.09% | 0.00% |
| Total Other Income/Expenses | -28.92K | 530.49K | -30.77K |
| Income Before Tax | -1.71M | 410.00K | -210.39K |
| Income Before Tax Ratio | -12,086.93% | 1,232.11% | 0.00% |
| Income Tax Expense | -199.00 | 0.00 | 0.00 |
| Net Income | -1.71M | 410.00K | -210.39K |
| Net Income Ratio | -12,086.93% | 1,232.11% | 0.00% |
| EPS | -0.03 | 0.01 | 0.00 |
| EPS Diluted | -0.03 | 0.01 | 0.00 |
| Weighted Avg Shares Out | 54.85M | 51.61M | 43.27M |
| Weighted Avg Shares Out (Dil) | 54.85M | 51.61M | 43.27M |
Liviana Artisanal CBD Olive Oils Have Arrived
Wuhan General Group Secures Lab for Hemp and Mycelium Eco-Friendly Research & Development
Wuhan General Group Recruiting in Lesotho for its Medicinal Cannabis Cultivation Facility
Medspresso(TM) Partners with CNC Products for Online Listing and CSR Activities
Wuhan General Group Introduces Liviana(TM) CBD Infused Artisanal Olive Oil
CORRECTION: Wuhan Launches Medspresso CBD Infused Whole Bean Roasted Coffee
Wuhan Launches Medspresso CBD Infused Whole Bean Roasted Coffee
Wuhan General Group Closes Acquisition of Tsime Pharmaceuticals (PTY) Limited
Source: https://incomestatements.info
Category: Stock Reports